Pfizer Inc.
Dear Inner Circle Member,
In July 2011 we analyzed Pfizer’s prospects and felt it offered our readers a strong combination of long-term growth and income. We—and you—have not been disappointed. The stock touched a new all-time high of $51.86 in August 2021, which is an impressive 159.3% above the $20 that the stock was trading for when we first recommended it in our Wall Street Stock Forecaster newsletter....
In July 2011 we analyzed Pfizer’s prospects and felt it offered our readers a strong combination of long-term growth and income. We—and you—have not been disappointed. The stock touched a new all-time high of $51.86 in August 2021, which is an impressive 159.3% above the $20 that the stock was trading for when we first recommended it in our Wall Street Stock Forecaster newsletter....
In 2019, Pfizer decided to focus on its main prescription drug business, which offers investors higher long-term returns than either over-the-counter and generic drugs.
As part of that plan, on November 16, 2020, the pharma giant combined its Upjohn division (generic pharmaceuticals) with Netherlands-based Mylan N.V....
As part of that plan, on November 16, 2020, the pharma giant combined its Upjohn division (generic pharmaceuticals) with Netherlands-based Mylan N.V....
In May 2021, Brooks Automation, a leading supplier of robotic handling and sorting equipment to manufacturers, announced that it would spin off its semiconductor-related operations as a separate firm.
However, Brooks decided instead to sell this business to private equity firm Thomas H....
However, Brooks decided instead to sell this business to private equity firm Thomas H....
The Covid-19 pandemic has pushed shares prices for many healthcare stocks—and the ETFs that hold them—to today’s all-time highs. Despite that, the underlying growth trends remain strong as the global population grows older and emerging economies spend more on healthcare....
Pfizer’s shares hit a new all-time high of $52 in August 2021 thanks largely to the huge success of its COVID-19 vaccine. New orders for the vaccine, as well as its other drugs as hospitals resume normal operations, should continue to fuel its share price gains—and your dividends.
PFIZER INC....
PFIZER INC....
PFIZER INC. $48 is a buy. The prescription drug maker (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $268.8 billion; Price-to-sales ratio: 4.8; Dividend yield: 3.3%; TSINetwork Rating: Above Average; www.pfizer.com) hit a new all-time high of $52 in August 2021, thanks largely to the success of the COVID-19 vaccine it developed in partnership with German drugmaker BioNTech (Nasdaq symbol BNTX)....
Long-time readers know that we keep you informed of important news about the stocks we cover. That means highlighting developments or strategies that promise to brighten your prospects. Here are two buys that stand out this month:
THERMO FISHER SCIENTIFIC INC....
THERMO FISHER SCIENTIFIC INC....
Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company....
The company now plans to re energize its growth by spinning off its consumer business as a separate company....
VIATRIS INC. $15 (www.viatris.com) is a hold. The company took its current form on November 16, 2020, when Pfizer Inc. combined its Upjohn division (generic pharmaceuticals) with Netherlands-based Mylan N.V. (Nasdaq symbol MYL). Pfizer investors received 0.124079 of a share in the new firm for each share they held....
We have selected Choice Properties REIT as one of our three top picks for 2021 (BCE and Pfizer are the other two picks).
The units held up well last year—and the trust maintained its distributions—despite retail shutdowns due to COVID-19. That’s mainly because its high-quality tenants, such as supermarkets and pharmacies, remained open as “essential” businesses....
The units held up well last year—and the trust maintained its distributions—despite retail shutdowns due to COVID-19. That’s mainly because its high-quality tenants, such as supermarkets and pharmacies, remained open as “essential” businesses....